The authors identified delayed removal of Miro1 from the OMM during mitophagy using PD patient fibroblasts, and they suggest that evaluation of Miro1 removal in fibroblast biopsies could be used to select patients who would benefit from treatment with a Miro1 reducer (27, 128). This evidence concerns the gene RHOT1 and Parkinson disease.